MDT

86.05

+0.2%↑

A

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

MDT

86.05

+0.2%↑

A

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

MDT

86.05

+0.2%↑

A

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

MDT

86.05

+0.2%↑

A

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

MDT

86.05

+0.2%↑

A

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

Search

Kala Pharmaceuticals Inc

Open

0.15 -6.25

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.12

Max

0.16

Belangrijke statistieken

By Trading Economics

Inkomsten

3.6M

-7.6M

Dividenden

By Dow Jones

Volgende Winsten

6 apr 2026

Kala Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 apr 2026, 22:56 UTC

Belangrijke Nieuwsgebeurtenissen

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 apr 2026, 20:50 UTC

Acquisities, Fusies, Overnames

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 apr 2026, 23:55 UTC

Marktinformatie

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 apr 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 apr 2026, 23:23 UTC

Belangrijke Nieuwsgebeurtenissen

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 apr 2026, 23:07 UTC

Winsten

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 apr 2026, 23:02 UTC

Belangrijke Nieuwsgebeurtenissen

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 apr 2026, 23:00 UTC

Belangrijke Nieuwsgebeurtenissen

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 apr 2026, 23:00 UTC

Belangrijke Nieuwsgebeurtenissen

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 apr 2026, 23:00 UTC

Belangrijke Nieuwsgebeurtenissen

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 apr 2026, 22:39 UTC

Winsten

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 apr 2026, 22:08 UTC

Marktinformatie

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 apr 2026, 22:00 UTC

Belangrijke Nieuwsgebeurtenissen

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 apr 2026, 21:56 UTC

Acquisities, Fusies, Overnames

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 apr 2026, 21:31 UTC

Belangrijke Nieuwsgebeurtenissen

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 apr 2026, 20:38 UTC

Winsten

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 apr 2026, 20:31 UTC

Acquisities, Fusies, Overnames

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 apr 2026, 20:16 UTC

Acquisities, Fusies, Overnames

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 apr 2026, 20:16 UTC

Acquisities, Fusies, Overnames

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 apr 2026, 20:13 UTC

Acquisities, Fusies, Overnames

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 apr 2026, 20:07 UTC

Marktinformatie

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 apr 2026, 20:07 UTC

Acquisities, Fusies, Overnames

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Peer Vergelijking

Prijswijziging

Kala Pharmaceuticals Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Winst voor belastingen

Verkoop

Rente-uitgaven op schulden

Operationele winst

$

Over Kala Pharmaceuticals Inc

Kala Pharmaceuticals Inc
help-icon Live chat